Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | LYN | P07948 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 5/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | HCK | P08631 | 2/20 | 0.44 |
| ▸ | CIT | O14578 | 1/20 | 0.44 |
| ▸ | MUSK | O15146 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | STK10 | O94804 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177761 | 0.88 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL4167498 | 0.86 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK9MAPK11 | |
| SCHEMBL1408447 | 0.81 | HRH3 (0.46) | MAPK14MAPK13MAPK12MAPK9MAPK11 | |
| SCHEMBL26925441 | 0.80 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK9MAPK11 | |
| SCHEMBL13852786 | 0.80 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK9MAPK11 | |
| SCHEMBL5047327 | 0.78 | PARP1 (0.48) | MAPK14MAPK13MAPK12MAPK9MAPK11 | |
| SCHEMBL4170616 | 0.77 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4168970 | 0.76 | CDK8 (0.50) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL28697180 | 0.76 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK9MAPK11 | |
| SCHEMBL4156005 | 0.74 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004653-B1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-A]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-30 | — | — | EP | claimed |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | claimed |
| EP-2004653-B1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-A]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| EP-2004652-A1 | 3-UNSUBSTITUTED N-(ARYL- OR HETEROARVL)-PYRAZOLORI Ý1,5-A¨PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| EP-2004653-A1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-a]PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113000-A1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-a]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007112998-A1 | 3-UNSUBSTITUTED N-(ARYL- OR HETEROARVL)-PYRAZOLORI [1,5-A]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | MAPK14 487/4885MAPK13 373/4885MAPK12 553/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | MAPK14 473/4885MAPK13 383/4885MAPK12 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.